| Income Statement | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-09-30 |
|---|---|---|---|---|
| Fair value loss on investments in equity securities | 0 | 51,002 | - | - |
| Provision for expected credit losses | 175,818 | 0 | - | - |
| Total operating expenses | 1,187,954 | 1,188,776 | -1,053,331 | - |
| Loss from operations | -702,509 | -611,293 | -618,418 | -1,337,622 |
| Interest expense, operating and nonoperating | - | - | - | 6,193 |
| Finance costs | 6,482 | 4,879 | 4,909 | - |
| Loss before tax | -708,991 | -616,172 | -623,327 | -1,343,815 |
| Tax expense | 0 | 0 | - | 1,555 |
| Net loss attributable to common shareholders | -708,991 | -616,172 | -623,327 | -1,345,370 |
| Foreign currency translation gain/(loss) | - | - | 72,159 | 1,046,789 |
| Foreign currency translation gain | 3,216 | 367,078 | - | - |
| Comprehensive loss | -705,775 | -249,094 | -551,168 | -298,581 |
| Basic & diluted eps | - | - | - | -0.017 |
| Earnings per share - basic and diluted | -0.395 | -0.343 | -0.035 | - |
| Weighted average number of common stocks outstanding, basic and diluted | 1,796,597 | 1,796,597 | 17,967,663 | - |
BioNexus Gene Lab Corp (BGLC)
BioNexus Gene Lab Corp (BGLC)